Mucosal Melanoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MCS004 MIFTS: 49	Mucosal Melanoma Categories: Cancer diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Mucosal Melanoma

MalaCards integrated aliases for Mucosal Melanoma:

Name: Mucosal Melanoma ¹² ²⁹ ¹⁵ ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050929

UMLS ⁷³ C3898222

Sources

Summaries for Mucosal Melanoma

Disease Ontology : ¹² A melanoma that has material basis in melanocytes located in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract.

MalaCards based summary : Mucosal Melanoma is related to melanoma and skin melanoma. An important gene associated with Mucosal Melanoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Nicotinamide and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lymph node, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Wikipedia : ⁷⁶ Mucosal melanoma is a rare cutaneous condition characterized by a melanoma of the mucous... more...

Sources

Related Diseases for Mucosal Melanoma

Diseases related to Mucosal Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)

#	Related Disease	Score	Top Affiliating Genes
1	melanoma	32.1	BRAF MAGEC1 MITF NRAS
2	skin melanoma	29.9	BRAF MITF NRAS
3	malignant skin fibrous histiocytoma	29.8	KIT NRAS
4	acral lentiginous melanoma	29.5	BRAF KIT NRAS TERT
5	ovarian melanoma	10.2	KIT NRAS
6	conventional fibrosarcoma	10.2	KIT NRAS
7	amelanotic melanoma	10.2	BRAF KIT
8	erdheim-chester disease	10.2	BRAF NRAS
9	congenital mesoblastic nephroma	10.2	KIT NRAS
10	phakomatosis cesioflammea	10.2	GNA11 GNAQ
11	intraocular melanoma	10.2	GNA11 GNAQ
12	urachal adenocarcinoma	10.2	BRAF NF1
13	nodular malignant melanoma	10.2	GNAQ NRAS
14	plexiform schwannoma	10.2	KIT NF1
15	core binding factor acute myeloid leukemia	10.1	KIT NRAS
16	pilocytic astrocytoma of cerebellum	10.1	BRAF NF1
17	pilocytic astrocytoma	10.1	BRAF NF1
18	malignant dermis tumor	10.1	KIT NRAS
19	spermatocytoma	10.1	KIT MAGEC1
20	neurofibromatosis, type i	10.1	KIT NF1
21	myelodysplastic myeloproliferative cancer	10.1	NF1 NRAS
22	ocular melanoma	10.1	IL2 KIT
23	maxillary sinus adenoid cystic carcinoma	10.1	IL2 KIT
24	leopard syndrome	10.1	BRAF NF1
25	pilomyxoid astrocytoma	10.1	BRAF NF1
26	mast cell neoplasm	10.1	IL2 KIT
27	malignant conjunctival melanoma	10.0	GNA11 GNAQ NRAS
28	melanomatosis	10.0	GNA11 GNAQ NRAS
29	conjunctival cancer	10.0	GNA11 GNAQ NRAS
30	meningeal melanomatosis	10.0	GNA11 GNAQ NRAS
31	meningeal melanocytoma	10.0	GNA11 GNAQ NRAS
32	nervous system benign neoplasm	10.0	KIT NF1
33	gastrointestinal stromal tumor	10.0	BRAF KIT NF1
34	cutaneous ganglioneuroma	10.0	KIT MITF
35	juvenile myelomonocytic leukemia	10.0	BRAF NF1 NRAS
36	posterior uveal melanoma	10.0	BRAF MITF
37	pulmonic stenosis	10.0	BRAF NF1
38	breast angiosarcoma	10.0	KIT MITF
39	thymus gland disease	10.0	IL2 KIT
40	dowling-degos disease 1	10.0	KIT MITF
41	central nervous system melanocytic neoplasm	9.9	GNA11 GNAQ KIT NRAS
42	ocular cancer	9.9	GNA11 GNAQ IL2
43	lymphoma	9.9
44	thyroid cancer	9.9	BRAF KIT NRAS TERT
45	lymphoma, non-hodgkin, familial	9.9	BRAF IL2 NRAS
46	neurofibroma	9.9	KIT MITF NF1
47	vulvar melanoma	9.9	KIT NF1 NRAS TERT
48	myelodysplastic syndrome	9.8	KIT NF1 NRAS TERT
49	angiomyolipoma	9.8	KIT MITF
50	noonan syndrome 1	9.8	BRAF IL2 NF1 NRAS

Graphical network of the top 20 diseases related to Mucosal Melanoma:

Sources

Symptoms & Phenotypes for Mucosal Melanoma

MGI Mouse Phenotypes related to Mucosal Melanoma:

⁴⁶ (show all 23)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.23	BRAF GNA11 GNAQ IL2 KIT MITF
2	growth/size/body region	MP:0005378	10.22	BRAF GNA11 GNAQ IL2 KIT MITF
3	behavior/neurological	MP:0005386	10.21	BRAF GNA11 GNAQ IL2 KIT MITF
4	hematopoietic system	MP:0005397	10.2	BRAF GNA11 GNAQ IL2 KIT MITF
5	homeostasis/metabolism	MP:0005376	10.19	BRAF GNA11 GNAQ IL2 KIT MITF
6	immune system	MP:0005387	10.18	BRAF GNA11 GNAQ IL2 KIT MITF
7	cardiovascular system	MP:0005385	10.15	BRAF GNA11 GNAQ IL2 KIT NF1
8	cellular	MP:0005384	10.14	BRAF IL2 KIT MITF NF1 NRAS
9	craniofacial	MP:0005382	10.14	BRAF GNA11 GNAQ KIT MITF NF1
10	mortality/aging	MP:0010768	10.11	BRAF GNA11 GNAQ IL2 KIT MITF
11	digestive/alimentary	MP:0005381	10.06	BRAF IL2 KIT NF1 NRAS TERT
12	integument	MP:0010771	10.05	BRAF GNA11 GNAQ KIT MITF NF1
13	limbs/digits/tail	MP:0005371	10.04	BRAF GNA11 GNAQ KIT MITF NF1
14	hearing/vestibular/ear	MP:0005377	10.03	BRAF GNA11 GNAQ KIT MITF NF1
15	normal	MP:0002873	9.97	BRAF GNA11 GNAQ KIT MITF NF1
16	liver/biliary system	MP:0005370	9.95	BRAF GNA11 IL2 KIT NF1 NRAS
17	nervous system	MP:0003631	9.95	BRAF GNA11 GNAQ KIT MITF NF1
18	neoplasm	MP:0002006	9.91	BRAF IL2 KIT NF1 NRAS TERT
19	pigmentation	MP:0001186	9.87	BRAF GNA11 GNAQ KIT MITF NF1
20	respiratory system	MP:0005388	9.7	BRAF GNA11 GNAQ IL2 KIT NF1
21	renal/urinary system	MP:0005367	9.65	BRAF GNA11 GNAQ KIT NF1
22	skeleton	MP:0005390	9.56	BRAF GNA11 GNAQ KIT MITF NF1
23	vision/eye	MP:0005391	9.1	BRAF IL2 KIT MITF NF1 NRAS

Sources

Drugs & Therapeutics for Mucosal Melanoma

Drugs for Mucosal Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Nicotinamide

Approved, Investigational

Phase 3

98-92-0

936

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2

33069-62-4

36314

Sorafenib

Approved, Investigational

Phase 3

284461-73-0

216239 406563

Carboplatin

Approved

Phase 3,Phase 2

41575-94-4

10339178 38904 498142

Pembrolizumab

Approved

Phase 3,Phase 2,Phase 1

1374853-91-4

Temozolomide

Approved, Investigational

Phase 3

85622-93-1

5394

Dacarbazine

Approved, Investigational

Phase 3

4342-03-4

5351166

Cisplatin

Approved

Phase 3

15663-27-1

2767 441203 84093

Niacin

Approved, Investigational, Nutraceutical

Phase 3

59-67-6

938

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Imidacloprid

Vet_approved

Phase 3

105827-78-9

86418

Micronutrients

Phase 3

Folate

Phase 3

Nicotinic Acids

Phase 3

Vitamin B9

Phase 3

Trace Elements

Phase 3

Vitamins

Phase 3

Antimitotic Agents

Phase 3,Phase 2

Vitamin B3

Phase 3

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2

Vitamin B Complex

Phase 3

Albumin-Bound Paclitaxel

Phase 3,Phase 2

Protein Kinase Inhibitors

Phase 3,Phase 2

Immunologic Factors

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Alkylating

Phase 3

Antiviral Agents

Phase 3,Phase 2

Interferon-alpha

Phase 3,Phase 2

Anti-Infective Agents

Phase 3,Phase 2

Alkylating Agents

Phase 3

Krestin

Phase 3

interferons

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Sunitinib

Approved, Investigational

Phase 2

557795-19-4, 341031-54-7

5329102

Nivolumab

Approved

Phase 2,Phase 1

946414-94-4

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Aldesleukin

Approved

Phase 2

85898-30-2, 110942-02-4

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Everolimus

Approved

Phase 2

159351-69-6

6442177

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

46835353 6436030 5284616

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Serine

Approved, Nutraceutical

Phase 2

56-45-1

5951

tyrosine

Phase 2

Imatinib Mesylate

Phase 2

220127-57-1

123596

Angiogenesis Modulating Agents

Phase 2

Angiogenesis Inhibitors

Phase 2

Vaccines

Phase 2,Phase 1

Freund's Adjuvant

Phase 2,Phase 1

Adjuvants, Immunologic

Phase 2

Interventional clinical trials:

(show all 41)

#	Name	Status	NCT ID	Phase	Drugs
1	Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	Completed	NCT00110019	Phase 3	Carboplatin;Paclitaxel;Sorafenib Tosylate
2	HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma	Recruiting	NCT03435302	Phase 3	Temozolomide Plus Cisplatin;High-Dose IFN-a2b
3	High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery	Active, not recruiting	NCT02506153	Phase 3
4	A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread	Completed	NCT01395121	Phase 2	nilotinib
5	Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma	Completed	NCT00424515	Phase 2	Imatinib
6	Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma	Completed	NCT00881049	Phase 2	Imatinib (Gleevec)
7	SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma	Completed	NCT00577382	Phase 2	Sunitinib
8	Study of Nilotinib in Metastatic Melanoma With KIT Aberrations	Completed	NCT01099514	Phase 2	Nilotinib
9	THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease	Completed	NCT01355120	Phase 2	Ipilimumab
10	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	Completed	NCT01961115	Phase 2	Epacadostat
11	Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma	Completed	NCT00085189	Phase 2	Montanide ISA 51 VG;agatolimod sodium
12	The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery	Recruiting	NCT03178123	Phase 2
13	Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era	Recruiting	NCT03138642	Phase 2
14	Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma	Recruiting	NCT03313206	Phase 2	Pembrolizumab
15	Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma	Recruiting	NCT03241186	Phase 2	Ipilimumab;Nivolumab;Nivolumab
16	PLX3397 KIT in Acral aNd mucOsal Melanoma	Recruiting	NCT02071940	Phase 2	PLX3397
17	Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma	Recruiting	NCT02023710	Phase 2	Paclitaxel;Carboplatin;Bevacizumab
18	A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab	Recruiting	NCT02978443	Phase 2	Nivolumab;Ipilimumab
19	Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists	Recruiting	NCT02126579	Phase 1, Phase 2
20	Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma Patients	Recruiting	NCT03190824	Phase 2	OBP-301
21	Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib	Recruiting	NCT03235245	Phase 2	Nivolumab + Ipilimumab;Encorafenib + Binimetinib
22	Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	Recruiting	NCT02748564	Phase 2
23	Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery	Recruiting	NCT02519322	Phase 2
24	Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery	Recruiting	NCT03698019	Phase 2
25	Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery	Active, not recruiting	NCT00700882	Phase 2	dasatinib
26	Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery	Active, not recruiting	NCT02158520	Phase 2	Nab-paclitaxel
27	Dinaciclib in Treating Patients With Stage IV Melanoma	Active, not recruiting	NCT00937937	Phase 2	Dinaciclib
28	Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma	Active, not recruiting	NCT01827111	Phase 2	ABI-007;Ipilimumab
29	Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.	Not yet recruiting	NCT03758729	Phase 2	Nivolumab
30	Study of the Combination of CM082 With JS001 in Patients With Advanced Mucinous Melanoma.	Not yet recruiting	NCT03602547	Phase 2	CM082 plus JS001
31	CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma	Suspended	NCT02129075	Phase 2
32	Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma	Terminated	NCT01092728	Phase 2	Dasatinib
33	Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV	Terminated	NCT01166126	Phase 2	temsirolimus;selumetinib
34	Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients	Terminated	NCT00706992	Phase 2
35	A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma	Terminated	NCT01864538	Phase 2	TH-302
36	Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma	Withdrawn	NCT03220009	Phase 2
37	Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)	Completed	NCT02180061	Phase 1
38	Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured	Completed	NCT00798629	Phase 1
39	Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases	Recruiting	NCT02858869	Phase 1
40	Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease	Recruiting	NCT03025256	Phase 1
41	Molecular Characterization of Primary Mucosal Melanoma	Recruiting	NCT03319693

Search NIH Clinical Center for Mucosal Melanoma

Sources

Genetic Tests for Mucosal Melanoma

Genetic tests related to Mucosal Melanoma:

#	Genetic test	Affiliating Genes
1	Mucosal Melanoma ²⁹

Sources

Anatomical Context for Mucosal Melanoma

MalaCards organs/tissues related to Mucosal Melanoma:

⁴¹

Skin, T Cells, Lymph Node, Brain, Thymus, Cerebellum, Myeloid

The Foundational Model of Anatomy Ontology organs/tissues related to Mucosal Melanoma:

¹⁹

Mucosal Membranes Lining The Respiratory

Sources

Publications for Mucosal Melanoma

Articles related to Mucosal Melanoma:

(show top 50) (show all 328)

#	Title	Authors	Year
1	Mucosal melanoma: clinical and genetic profile. ( 29797459 )	Caius Silviu S....Stefania A.	2018
2	Clinical patterns and management of primary mucosal melanoma: a single centre experience. ( 29388353 )	Ng Y.Y.R....Teo M.C.C.	2018
3	Updates in the management of sinonasal mucosal melanoma. ( 29095708 )	Crippen M.M....Eloy J.A.	2018
4	Mucosal Melanoma: a Literature Review. ( 29569184 )	Yde S.S....Stolle L.B.	2018
5	Anorectal mucosal melanoma. ( 29492238 )	Malaguarnera G....Latteri S.	2018
6	Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma. ( 29044491 )	Amit M....Hanna E.Y.	2018
7	Primary sinonasal mucosal melanoma simulated as cystic lesions: a case report. ( 29535967 )	Shin S.H....Hong S.D.	2018
8	Reply to mucosal melanoma: clinical and genetic profile. ( 29799644 )	Cinotti E....Rubegni P.	2018
9	Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma. ( 29492677 )	Amit M....Hanna E.Y.	2018
10	Analysis of TSC1 mutation spectrum in mucosal melanoma. ( 29185092 )	Ma M....Guo J.	2018
11	Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. ( 29748886 )	Cui C....Guo J.	2018
12	Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. ( 29230811 )	Lyu J....Shi Y.	2018
13	Patterns of Treatment Failure in Patients with Sinonasal Mucosal Melanoma. ( 29626308 )	Amit M....Hanna E.Y.	2018
14	A comprehensive genome-wide analysis of the long noncoding RNA expression profile in metastatic lymph nodes of oral mucosal melanoma. ( 29960071 )		2018
15	Immunotherapy in mucosal melanoma: a case report and review of the literature. ( 29707161 )		2018
16	<i>KIT, NRAS, BRAF</i> and <i>FMNL2</i> mutations in oral mucosal melanoma and a systematic review of the literature. ( 29805686 )		2018
17	Are oral mucosal nevi potential precursors for oral mucosal melanoma? ( 29501410 )		2018
18	Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity. ( 29952773 )		2018
19	Genital mucosal melanoma with somatic SF3B1 R625C mutation. ( 29624176 )		2018
20	Combination therapy improves immune response and prognosis in patients with advanced oral mucosal melanoma: A clinical treatment success. ( 29958936 )		2018
21	Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients. ( 30447078 )	Maeda T...Hata H	2018
22	The existence of early stage oral mucosal melanoma: A 10-year retrospective analysis of 170 patients in a single institute. ( 30527246 )	Wu Y...Ren G	2018
23	Combatting mucosal melanoma: recent advances and future perspectives. ( 30459941 )	Tyrrell H...Payne M	2018
24	Similar survival outcome after endoscopic and open approaches for sinonasal mucosal melanoma. ( 30471227 )	Lundberg M...Vento SI	2018
25	SPRED1 Is a Tumor Suppressor in Mucosal Melanoma. ( 30413408 )		2018
26	The Pedunculated Pretender: A Case of Invasive Anorectal Mucosal Melanoma. ( 30454500 )	Hall ME...Hawkins AT	2018
27	Prognostic factors and incidence of primary mucosal melanoma: a population-based study in France. ( 30378540 )	Beaudoux O...Grange F	2018
28	Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. ( 30385465 )	Ablain J...Yeh I	2018
29	Altered expression pattern of circular RNAs in metastatic oral mucosal melanoma. ( 30323971 )	Ju H...Ren G	2018
30	Predictors of mucosal melanoma survival in a population-based setting. ( 30296542 )	Altieri L...Cockburn M	2018
31	The evaluation of malignant mucosal melanoma of nasal cavity with a rare occasion. ( 30245777 )	Kepekci AH...Gundogan GI	2018
32	Prognosis of endoscopic surgery and traditional open resection in mucosal melanoma of the nasal cavity and paranasal sinus. ( 30256270 )	Yin G...Huang Z	2018
33	ASO Author Reflections: Treatment Approaches to Sinonasal Mucosal Melanoma. ( 30267288 )	Amit M...Hanna EY	2018
34	The Pedunculated Pretender: A Case of Invasive Anorectal Mucosal Melanoma. ( 30269709 )	Hall ME...Hawkins AT	2018
35	Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody. ( 30199578 )	Yamashita C...Kabashima K	2018
36	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. ( 30202085 )	Hamid O...Butler M	2018
37	Primary Mucosal Melanoma of the Stomach. ( 30159179 )	Phillips O...Fish H	2018
38	Primary and secondary mucosal melanoma of the small intestine - a clinical, pathological, and genetic nationwide survey of Danish patients between 1980 and 2014. ( 30160023 )	Tingsgaard JK...Heegaard S	2018
39	Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. ( 30177220 )	Allanson BM...Scolyer RA	2018
40	Primary malignant melanoma of esophagus shared similar genetic characters with both cutaneous and oral mucosal melanoma. ( 30023129 )	Li J...Wu N	2018
41	Successful rechallenge with nivolumab therapy after radiotherapy in mucosal melanoma. ( 30035312 )	Kato J...Uhara H	2018
42	Mucosal melanoma of the cranio-facial region: Surgical challenges and therapeutic options. ( 30082161 )	Thierauf J...Bergmann C	2018
43	Primary Middle Ear Mucosal Melanoma: Case Report and Comprehensive Literature Review of 21 Cases of Primary Middle Ear and Eustachian Tube Melanoma. ( 30103615 )	Maxwell AK...Gubbels SP	2018
44	Predominance of oral mucosal melanoma in areas of high mechanical stress. ( 30138653 )	Rambhia PH...Arbesman J	2018
45	Radiotherapy alone as a method of treatment for sinonasal mucosal melanoma: A report based on six cases and a review of current opinion. ( 30147451 )	Sas-Korczynska B...Walasek T	2018
46	The clinical significance of<i>c-Kit</i>mutations in metastatic oral mucosal melanoma in China. ( 29137292 )	Ma X....Ren G.	2017
47	Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma. ( 28134726 )	Hsieh R....LourenAso S.V.	2017
48	Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution. ( 29103739 )	Sun S....Yi J.	2017
49	Mucosal Melanoma Originating From the Eustachian Tube. ( 28953148 )	Kim J.H....Kang J.W.	2017
50	Failure patterns and prognostic factors of patients with primary mucosal melanoma of the nasal cavity and paranasal sinuses. ( 28767022 )	Liu Z.P....Xiao J.P.	2017

Sources

Genes for Mucosal Melanoma

Genes related to Mucosal Melanoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	Protein Coding	24.62	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	24.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	GNAQ	G Protein Subunit Alpha Q	Protein Coding	22.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	MITF	Melanocyte Inducing Transcription Factor	Protein Coding	22.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	GNA11	G Protein Subunit Alpha 11	Protein Coding	21.69	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	NF1	Neurofibromin 1	Protein Coding	21.09	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	MAGEC1	MAGE Family Member C1	Protein Coding	20.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	TERT	Telomerase Reverse Transcriptase	Protein Coding	20.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	20.64	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	IL2	Interleukin 2	Protein Coding	20.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Mucosal Melanoma

Sources

Expression for Mucosal Melanoma

Search GEO for disease gene expression data for Mucosal Melanoma.

Sources

Pathways for Mucosal Melanoma

Pathways related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 44)

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by GPCR ⁶⁶ Show member pathways GPCR downstream signaling ⁶⁶ Signal Transduction ⁶⁶	13.95	BRAF GNA11 GNAQ IL2 KIT NF1
2	Apoptotic Pathways in Synovial Fibroblasts ⁶⁴ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶⁴ Cellular Apoptosis Pathway ⁶⁴ DHA Signaling ⁶⁴ eIF2 Pathway ⁶⁴ ERK5 Signaling ⁶⁴ Glioma Invasiveness ⁶⁴ Mitochondrial Apoptosis ⁶⁴ Nuclear Receptor Activation by Vitamin-A ⁶⁴ p53 Mediated Apoptosis ⁶⁴ PPAR Pathway ⁶⁴ Rac1 Pathway ⁶⁴ Rap1 Pathway ⁶⁴ Telomerase Components in Cell Signaling ⁶⁴	13.66	BRAF GNA11 GNAQ IL2 KIT NRAS
3	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.17	BRAF IL2 KIT NF1 NRAS
4	IL-2 Pathway ⁶⁴ Show member pathways ErbB Family Pathway ⁶⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-4 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ Prolactin Signaling ⁶⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.02	BRAF GNA11 GNAQ IL2 NRAS
5	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.82	IL2 KIT NRAS TERT
6	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	12.8	BRAF GNA11 IL2 KIT NRAS
7	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.62	BRAF GNA11 GNAQ KIT NRAS
8	MAPK-Erk Pathway ⁶⁷ Show member pathways Actin Dynamics Signaling Pathway ⁶⁷ G Protein-coupled Receptors Signaling ⁶⁷	12.6	BRAF GNA11 MITF NRAS
9	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.59	BRAF MITF NF1 NRAS
10	MAPK signaling pathway ³⁷ ¹	12.58	BRAF KIT NF1 NRAS
11	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.57	BRAF KIT NRAS TERT
12	Vascular smooth muscle contraction ³⁷ Show member pathways cGMP-PKG signaling pathway ³⁷ Oxytocin signaling pathway ³⁷	12.51	BRAF GNA11 GNAQ NRAS
13	Ras signaling pathway ³⁷ Show member pathways Rap1 signaling pathway ³⁷	12.44	BRAF GNAQ KIT NF1 NRAS
14	RANK Signaling in Osteoclasts ⁶⁴ Show member pathways Apoptosis and survival APRIL and BAFF signaling ²² APRIL Pathway ⁶⁴ BAFF in B-Cell Signaling ⁶⁴ RANK Pathway ⁶⁴ RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway ¹	12.27	BRAF MITF NRAS
15	Human T-cell leukemia virus 1 infection ³⁷	12.26	IL2 NRAS TERT
16	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ¹	12.22	BRAF IL2 KIT NRAS
17	Paradoxical activation of RAF signaling by kinase inactive BRAF ⁶⁶ Show member pathways MAP2K and MAPK activation ⁶⁶ Signaling by high-kinase activity BRAF mutants ⁶⁶ Signaling by moderate kinase activity BRAF mutants ⁶⁶ Signaling by RAS mutants ⁶⁶	12.13	BRAF NF1 NRAS
18	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Show member pathways Activation of the AP-1 family of transcription factors ⁶⁶ Immune response Oncostatin M signaling via MAPK in human cells ²² MAPK Cascade ¹ Oncostatin M Signaling Pathway ¹	12.09	BRAF MITF NRAS
19	G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins ²² Show member pathways G-protein signaling G-Protein alpha-12 signaling pathway ²²	12.05	BRAF GNA11 GNAQ NRAS
20	Long-term potentiation ³⁷ Show member pathways Common Pathways Underlying Drug Addiction ¹ Dopamine D1-Like Receptor Family Signaling Pathways ⁶⁵	12.04	BRAF GNAQ NRAS
21	Pathways in cancer ³⁷	11.95	BRAF GNA11 GNAQ IL2 KIT MITF
22	Oncogenic MAPK signaling ⁶⁶ Show member pathways Signaling by BRAF and RAF fusions ⁶⁶	11.89	BRAF NF1 NRAS
23	UVA-Induced MAPK Signaling ⁶⁴ Show member pathways UVB-Induced MAPK Signaling ⁶⁴	11.88	GNA11 GNAQ NRAS
24	Cushing syndrome ³⁷ Show member pathways Melanogenesis ³⁷	11.84	BRAF GNA11 GNAQ KIT MITF NRAS
25	Development A2A receptor signaling ²² Show member pathways Development A2B receptor- action via G-protein alpha s ²²	11.83	BRAF GNA11 GNAQ
26	Serotonergic synapse ³⁷	11.78	BRAF GNAQ NRAS
27	Glioblastoma Multiforme ⁶⁴	11.76	BRAF NF1 NRAS
28	Parathyroid hormone synthesis, secretion and action ³⁷	11.73	BRAF GNA11 GNAQ
29	MAP Kinase Signaling ⁴	11.72	BRAF GNAQ NF1 NRAS
30	Gap junction ³⁷	11.6	GNA11 GNAQ NRAS
31	VEGF Pathway (Tocris) ⁶¹ Show member pathways VEGF Pathway ⁷²	11.53	BRAF KIT NRAS
32	Corticotropin-releasing hormone signaling pathway ¹	11.53	BRAF GNA11 GNAQ IL2
33	G-protein signaling_RhoA regulation pathway ²²	11.41	BRAF GNA11 GNAQ IL2 NRAS
34	Vemurafenib Pathway, Pharmacodynamics ⁶¹	11.31	BRAF NRAS
35	Melanocyte Development and Pigmentation ⁶⁴	11.3	KIT MITF
36	Development_Hedgehog and PTH signaling pathways in bone and cartilage development ²²	11.27	GNA11 GNAQ
37	G-protein signaling_Cross-talk between Ras-family GTPases ²²	11.24	BRAF GNA11 NRAS
38	Long-term depression ³⁷	11.23	BRAF GNA11 GNAQ NRAS
39	CFTR-dependent regulation of ion channels in Airway Epithelium (norm and CF) ²²	11.22	GNA11 GNAQ
40	Arf6 signaling events ¹	11.2	GNA11 GNAQ
41	BDNF-TrkB Signaling ¹	11.2	BRAF NRAS
42	Transcription_Transcription factor Tubby signaling pathways ²²	11.09	GNA11 GNAQ NRAS
43	Serotonin Receptor 2 and ELK-SRF/GATA4 signaling ¹	10.93	GNAQ NRAS
44	Free fatty acids regulate insulin secretion ⁶⁶ Show member pathways Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion ⁶⁶	10.8	GNA11 GNAQ

Sources

GO Terms for Mucosal Melanoma

Cellular components related to Mucosal Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	heterotrimeric G-protein complex	GO:0005834	8.62	GNA11 GNAQ

Biological processes related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 16)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	9.99	BRAF GNA11 GNAQ KIT NF1 NRAS
2	negative regulation of apoptotic process	GO:0043066	9.72	BRAF IL2 KIT MITF TERT
3	T cell differentiation	GO:0030217	9.56	IL2 KIT
4	negative regulation of endothelial cell apoptotic process	GO:2000352	9.55	BRAF TERT
5	response to cadmium ion	GO:0046686	9.54	KIT TERT
6	melanocyte differentiation	GO:0030318	9.52	KIT MITF
7	action potential	GO:0001508	9.49	GNA11 GNAQ
8	G protein-coupled acetylcholine receptor signaling pathway	GO:0007213	9.48	GNA11 GNAQ
9	developmental pigmentation	GO:0048066	9.46	GNA11 KIT
10	regulation of cell proliferation	GO:0042127	9.46	BRAF KIT MITF NF1
11	phototransduction, visible light	GO:0007603	9.43	GNA11 GNAQ
12	visual learning	GO:0008542	9.43	BRAF KIT NF1
13	entrainment of circadian clock	GO:0009649	9.4	GNA11 GNAQ
14	myeloid progenitor cell differentiation	GO:0002318	9.37	BRAF KIT
15	pigmentation	GO:0043473	9.13	KIT MITF NF1
16	MAPK cascade	GO:0000165	9.02	BRAF IL2 KIT NF1 NRAS

Molecular functions related to Mucosal Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	G-protein beta/gamma-subunit complex binding	GO:0031683	9.16	GNA11 GNAQ
2	guanyl nucleotide binding	GO:0019001	8.96	GNA11 GNAQ
3	type 2A serotonin receptor binding	GO:0031826	8.62	GNA11 GNAQ

Sources

Sources for Mucosal Melanoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia